Welcome to our dedicated page for Oramed Pharmaceuticals news (Ticker: ORMP), a resource for investors and traders seeking the latest updates and insights on Oramed Pharmaceuticals stock.
Oramed Pharmaceuticals Inc. develops oral drug delivery technology for drugs commonly delivered by injection. Its Protein Oral Delivery, or POD, platform is designed to protect therapeutic proteins in the gastrointestinal tract and improve absorption, with company updates centered on oral insulin development and related clinical-stage programs.
Oramed news also covers its expanded strategic investment activity, including positions and agreements involving Scilex and Alpha Tau Medical, as well as financial results, cash returns, dividend actions, shareholder rights matters, and other capital-structure developments. Recurring announcements connect the company’s pharmaceutical platform with its investment portfolio, governance actions, and operating expenses.
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) has received a patent from the European Patent Office for its innovative methods to treat non-alcoholic fatty liver disease (NAFLD) and hepatic steatosis. This patent complements a previously granted U.S. patent and is pending approval in various key markets. Additionally, Oramed has successfully completed 100% enrollment in its Phase 2 trial for oral insulin ORMD-0801, targeting type 2 diabetes patients with non-alcoholic steatohepatitis (NASH). The NASH drug market is projected to reach $84 billion by 2029.
Summary not available.
Oramed Pharmaceuticals (Nasdaq: ORMP) will host a webinar on March 30, 2022, at 12:00 p.m. ET, featuring experts discussing the need for oral insulin in type 2 diabetes. Presenters include Dr. Anne Peters from USC and Dr. Alexander Fleming, formerly with the FDA. They will address the treatment landscape and the potential of Oramed's oral insulin candidate, ORMD-0801, currently in Phase 3 trials. A live Q&A session will follow. For registration, visit here.
Oramed Pharmaceuticals (Nasdaq: ORMP) has successfully completed patient enrollment for its Phase 2 trial of the oral insulin capsule ORMD-0801, targeting non-alcoholic steatohepatitis (NASH) in Type 2 diabetes patients. NASH affects 4 to 17 million adults in the U.S., with no approved treatments currently available. The trial, conducted in the U.S. and Israel, will evaluate ORMD-0801's safety and efficacy after 12 weeks of dosing. The global NASH drug market is projected to reach $84 billion by 2029. Oramed anticipates reporting topline results that support previous efficacy findings.
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) announced that CEO Nadav Kidron will present at the Barclays Global Healthcare Conference in Miami, Florida, from March 15-17, 2022. Kidron's presentation is scheduled for Tuesday, March 15, 2022, at 3:50 p.m. Eastern time. The event will be webcasted and available for view for 90 days. Oramed is a pioneer in oral drug delivery systems, particularly targeting diabetes treatment with its lead oral insulin candidate, ORMD-0801, currently in pivotal Phase 3 studies.
Oramed Pharmaceuticals (NASDAQ: ORMP) provided a shareholder update highlighting significant advancements in 2021. The company is advancing its oral insulin and COVID-19 vaccine candidates through pivotal trials, expecting topline results in H2 2022. ORMP has achieved over 75% enrollment in its Phase 3 oral insulin trial and is progressing with its oral COVID-19 vaccine in South Africa. With approximately $174 million in cash as of December 2021, Oramed is well-positioned for upcoming milestones, including key clinical results and potential emergency use authorization for its vaccine.
Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) announced that the European Patent Office has granted it a patent for its oral protein delivery platform technology, supporting its lead drug candidate ORMD-0801, which is undergoing pivotal Phase 3 studies. This patent involves a novel method for purifying protease inhibitors, vital for protecting therapeutic proteins during digestion. With this patent, Oramed now holds 88 patents and 35 pending, enhancing its intellectual property position in the oral delivery market for therapeutics, specifically for diabetes treatment.
MyMD Pharmaceuticals has announced that its investment company, Oravax Medical, signed a Cooperation and Purchase Agreement with Vietnam's Tan Thanh Holdings for an initial pre-order of 10 million doses of an oral COVID-19 vaccine currently under development. The deal also allows for significant follow-on orders. Oravax's vaccine targets less mutable proteins and has benefits in logistics due to simplified storage requirements. MyMD holds a 13% stake in Oravax, along with a 2.5% royalty on future net sales. This agreement may boost revenue potential for both companies in the ASEAN region.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced that its subsidiary, Oravax Medical, has signed a Cooperation and Purchase Agreement with Vietnam's Tan Thanh Holdings. This agreement involves an initial pre-order of 10 million doses of an oral COVID-19 vaccine currently in development, with potential follow-on orders worth hundreds of millions. Tan Thanh will fund advanced clinical trials and regulatory approval, targeting the ASEAN market. Oravax's vaccine aims to combat COVID-19 variants and offers logistical advantages. The ASEAN pharmaceutical market is valued at $25 billion and is growing rapidly.
Oramed Pharmaceuticals announced the enrollment of the first participant in a Phase 1 clinical trial for its oral COVID-19 vaccine, developed by subsidiary Oravax Medical, in Johannesburg, South Africa. The trial aims to assess safety, tolerability, and efficacy while targeting three SARS-CoV-2 surface proteins, potentially increasing effectiveness against variants. The study will enroll 24 participants unvaccinated and without prior infection, with doses administered three weeks apart. Oramed anticipates rapid progress towards pivotal trials for emergency use approval, highlighting the vaccine's scalable manufacturing and distribution advantages.